Cognition Therapeutics Inc (NASDAQ:CGTX) shares, rose in value on Thursday, April 16, with the stock price down by -0.21% to the previous day’s close as strong demand from buyers drove the stock to $0.37.
Actively observing the price movement in the last trading, the stock closed the session at $0.37, falling within a range of $0.3599 and $0.3964. The value of beta (5-year monthly) was 1.002. Referring to stock’s 52-week performance, its high was $2.95, and the low was $0.31. On the whole, CGTX has fluctuated by -17.24% over the past month.
With the market capitalization of Cognition Therapeutics Inc currently standing at about $23.08 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-19.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CGTX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CGTX currently trading nearly -5.34% and -19.20% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.15, while the 7-day volatility ratio is showing 10.27% which for the 30-day chart, stands at 10.95%. Furthermore, Cognition Therapeutics Inc (CGTX)’s beta value is 1.00, and its average true range (ATR) is 0.04.
A comparison of Cognition Therapeutics Inc (CGTX) with its peers suggests the former has fared considerably weaker in the market. CGTX showed an intraday change of -0.21% in last session, and over the past year, it shrunk by -80.30%%.
Data on historical trading for Cognition Therapeutics Inc (NASDAQ:CGTX) indicates that the trading volumes over the past 10 days have averaged 0.55 and over the past 3 months, they’ve averaged 1.40 million. According to company’s latest data on outstanding shares, there are 59.85 million shares outstanding.
Nearly 18.96% of Cognition Therapeutics Inc’s shares belong to company insiders and institutional investors own 8.24% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.54 million shares as on 2025-03-31, resulting in a short ratio of 2.33. According to the data, the short interest in Cognition Therapeutics Inc (CGTX) stood at 311.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.11 million. The stock has fallen by -46.90% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CGTX stock heading into the next quarter.
